Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20288319 | 0.86 | HTR3A (0.54) | POLBSMN1; SMN2ALDH1A1TSHRMAPK1 | |
| SCHEMBL9170525 | 0.81 | ALDH1A1 (0.60) | POLBSMN1; SMN2ALDH1A1TSHRSMO | |
| SCHEMBL1708343 | 0.81 | POLB (0.58) | POLBSMN1; SMN2ALDH1A1TSHRGBA1 | |
| SCHEMBL25695026 | 0.80 | ALDH1A1 (0.47) | POLBSMN1; SMN2ALDH1A1TSHRMAPK1 | |
| SCHEMBL2255793 | 0.78 | POLB (0.47) | POLBSMN1; SMN2ALDH1A1TSHRGBA1 | |
| SCHEMBL18005507 | 0.77 | POLB (0.54) | POLBSMN1; SMN2ALDH1A1TSHRGBA1 | |
| SCHEMBL26077302 | 0.76 | POLB (0.62) | POLBSMN1; SMN2ALDH1A1TSHRGBA1 | |
| SCHEMBL9966953 | 0.76 | RPS6KA5 (0.46) | POLBSMN1; SMN2ALDH1A1RPS6KA5TSHR | |
| SCHEMBL2555821 | 0.76 | CYP3A4 (0.51) | POLBSMN1; SMN2ALDH1A1SMOHCRTR2 | |
| SCHEMBL26975238 | 0.74 | POLB (0.44) | POLBSMN1; SMN2ALDH1A1GBA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100465164-C | CF3Selective synthesis of-substituted pyrimidines | PFIZER (US) | 2009-03-04 | — | — | CN | disclosed |
| EP-1663991-B1 | SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES | PFIZER PROD INC (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1663991-B1 | SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES | PFIZER PROD INC (US) | 2007-01-10 | — | — | EP | disclosed |
| US-7122670-B2 | Selective synthesis of CF3-substituted pyrimidines | PFIZER INC (US) | 2006-10-17 | — | — | US | disclosed |
| CN-1845906-A | Selective synthesis of CF 3-substituted pyrimidines | PFIZER (US) | 2006-10-11 | — | — | CN | disclosed |
| EP-1663991-A1 | SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES | Pfizer Products Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050101620-A1 | Selective synthesis of CF3-substituted pyrimidines | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005023780-A1 | SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES | PFIZER PRODUCTS INC. (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101620-A1 | Selective synthesis of CF3-substituted pyrimidines | HNRNPH3, HNRNPA3, NUDT1 | POLB 910/4885SMN1; SMN2 2052/4885ALDH1A1 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.